Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00315185 · ClinicalTrials.gov registry record · Phase 2

Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Fox Chase Cancer Center.

Completed
Registry status
Phase 2
Development phase
53
Enrollment target
1
Study location

NCT00315185: Completed Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Fox Chase Cancer Center.

NCT00315185 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 53 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00315185, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Fox Chase Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
53 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the role of cetuximab (Erbitux) with chemotherapy for advanced colorectal carcinoma. This study will determine if this new agent can improve one's response to standard treatment.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Cetuximab

Study Locations (1)

Pennsylvania

  • Consultants in Medical Oncology & Hematology Inc. - Drexel Hill

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2004-12
Est. Completion 2008-06
Phase Phase 2
Fox Chase Cancer Center

183 total trials

What the finished NCT00315185 record still lists

NCT00315185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Cetuximab is the first listed.

NCT00315185 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00315185 about?

NCT00315185 is a clinical study titled "Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer". The purpose of this study is to determine the role of cetuximab (Erbitux) with chemotherapy for advanced colorectal carcinoma. This study will determine if this new agent can improve one's response to standard treatment.

What is the current status of trial NCT00315185?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2004-12. Estimated completion is 2008-06.

What conditions does trial NCT00315185 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT00315185?

The interventions under investigation include: Cetuximab (DRUG).

Who is sponsoring clinical trial NCT00315185?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00315185 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00315185's enrollment target sits among peer trials

53 92nd of 130 higher than 39 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04177004 · 53 participants · Phase 1

    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

  • NCT04199741 · 53 participants · Phase 1

    PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

  • NCT04835129 · 53 participants · Phase 2

    Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

  • NCT04913805 · 53 participants · Phase 2

    Matching Perfusion and Metabolic Activity in HFpEF

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00315185, the US trial registry maintained by the National Library of Medicine. NCT00315185 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.